Johnson & Johnson (JNJ)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $645.95B
Last updated: Sep 01, 2026 at 10:00 AM ET
Earnings
Performance (10Y)
Upcoming Estimates
Dividends
Dividend Metrics
Growth
Key Metrics
Technical Indicators Dashboard
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Data
Related GNG Research
The Diversification Test Every Investor Should Run (Built Into GNG)
Counting holdings is misleading - a 12-stock, 10-industry model that appeared diversified lost most diversification once positions were grouped by underlying return drivers Academic rules conflict on count - Evans & Archer (1968) says 10-15 stocks, Statman (1987) 30-40, Statman (2004) >300, all assume near-zero pairwise correlation (~0.08) Portfolio risk decomposes into idiosyncratic risk/N plus average covariance - the covariance is the non-diversifiable floor that additional names cannot breach Run the 20-minute test - build a pairwise correlation matrix or regress returns by economic drivers, compute average covariance and effective number of independent bets GNG embeds this test - prioritize holdings with distinct economic engines, size concentration to your demonstrated edge, and use ETF sleeves if you lack research bandwidth (peer uses 50% ETF)
Abbott: The Market Priced the Dent and Forgot the Cargo
Market punished Abbott - stock down ~34% from 52-week high $139.06 to ~$91, yet TTM revenue $45.1B, gross margin 56.4%, operating cash flow $9.46B and free cash flow $7.38B ($4.22/sh, 4.85% FCF yield) Closed oncology acquisition for ~$21B equity (~$23B incl assumed debt), funded with $20B notes, net debt ~ $27B, trims ~ $0.20 of adjusted EPS this year while adding ~$3B sales into a ~$60B oncology screening market FDA warning letter and Class I recall relate to CGM manufacturing controls, but regulators did not halt shipments - analysts expect limited near-term reported impact while Abbott completes corrective actions Dividend and balance-sheet intact - 50+ years of increases, quarterly $0.63 ($2.52/year) equals ~2.8% yield, payout ~45% of adjusted earnings, interest coverage >30x, Altman 2.97, Beneish indicates no manipulation Market pricing implies ~1.6% perpetual cash-flow growth versus management organic guide 6.5%-7.5%; blended fair value ~$112.50 implies 19% margin of safety and ~14% 12-month total return including the dividend
The Intelligent Compounder's Playbook: Five Dividend Aristocrats Built to Outlast the Next Downturn
Five dividend aristocrats stress-tested across 170+ quality metrics, ranked by conviction GNG Safety Scores span from 70.47 to a perfect 100 across the final five picks One insurer just posted record combined ratios and landed a $20B government contract The "cheapest" candidate on the screen carried an 876% payout ratio and got cut A 100th-percentile cash flow predictor is trading below its own recent average multiple The tactical value pick yields 3.9% with 8.58% FCF yield while margins normalize
Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To
Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined lenacapavir guide for 2026. Arcellx acquisition ($7.8B) adds anito-cel CAR-T for multiple myeloma. FDA decision Dec 23, 2026. Logical Kite extension, but differentiation burden is real. At ~17x forward EPS ($8.45-$8.85 guided), you pay fair value for the base and get oncology pipeline optionality essentially free. 2.1% yield while you wait. Vulcan scores: 93 Overall, 93 Value, 88 Quality, 95 Sentiment. Altman Z 4.6, Piotroski F 7, ROIC 19.6%, 78.7% gross margins. Fortress fundamentals. Part 1 of the Healthcare Barbell series: GILD anchors with defensive cash flows (0.37 beta). Part 2 (TMDX) and Part 3 (REGN) incoming. Invalidation: Biktarvy YoY declines in two consecutive quarters or EPS guides lower.
The Toll Booth on Biotech’s Highway: Why Halozyme’s Royalty Engine Could Make Patient Investors Rich
Halozyme's ENHANZE platform is a toll booth on injectable biologics: partners develop drugs, HALO collects royalties on every dose sold across 10 commercialized products in 100+ global markets. Three major deals in 100 days: Elektrofi acquisition ($750M+ in Oct), Skye Bioscience (Jan 5), and Takeda (Jan 8) expand the royalty runway and add obesity/IBD market exposure. Margins look like software, not biotech: 84.6% gross, 59.3% operating, 48% FCF yield. Interest coverage of 43x means the business can absorb setbacks without existential risk. At $71.67, HALO trades ~24% below DCF-blended fair value (~$92.5) with a forward PEG of 0.3x. Analyst targets range $58-$92, with recent upgrades to $90 from TD Cowen and Benchmark. Elektrofi's Hypercon technology extends delivery-tech IP into the 2040s, addressing the key bear case around ENHANZE patent duration risk in the late 2020s. Buy zone: $71-74 (current). Strong add: $62-69. Very strong: $56-62. Trim at $96-101. Invalidation trigger: two consecutive quarters of FCF decline without explanation. Key catalyst: Earnings mid-late Feb 2026. Watch royalty growth trajectory, Takeda/Skye integration commentary, and Hypercon partner clinical development progress by year-end.
News
Frequently Asked Questions About JNJ
- What is JNJ's current dividend yield?
- Johnson & Johnson (JNJ) has a current dividend yield of 1.99%.
- Does JNJ pay dividends?
- Yes, Johnson & Johnson pays dividends with a current yield of 1.99%.
- What is JNJ's P/E ratio?
- Johnson & Johnson has a price-to-earnings (P/E) ratio of 24.49.
- What is JNJ's market cap?
- Johnson & Johnson (JNJ) has a market capitalization of $645.95B with a current stock price of $265.91.
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.